Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest biopharmaceutical Stories

2013-12-18 12:26:58

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced the addition of Ronald G. Jubin, Ph.D. to their executive team as Managing Director, Research and Development. In his new role, Dr. Jubin will be responsible for pre-clinical discovery,...

2013-12-17 08:29:39

--Last patient dosed in moderate asthma trial and first patient dosed in COPD study-- QUEBEC CITY, Dec. 17, 2013 /PRNewswire/ -- Asmacure Ltee today announced that the company has completed dosing in a Phase 2 trial evaluating its lead compound, ASM-024, in moderate asthma patients, with data anticipated in the first quarter of 2014. The company also has begun patient enrollment in a Phase 2 trial of ASM-024 in patients with moderate and severe chronic obstructive pulmonary disease...

2013-12-17 04:20:56

COPENHAGEN, Denmark; SEATTLE; STRASBOURG, France; and SAN FRANCISCO, Dec. 17, 2013 /PRNewswire/ -- CMC Biologics and OncoSynergy announced today that the two companies entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy's OS2966 monoclonal antibody...

2013-12-12 12:26:31

MUMBAI, December 12, 2013 /PRNewswire/ -- A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of drug gable targets for monoclonal...

2013-12-11 23:22:41

ChinaMarketResearchReports.com adds “Global and China Insulin Industry Report, 2013-2017” latest report to its store. Dallas, TX (PRWEB) December 11, 2013 As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing...

2013-12-09 20:22:38

Four Presentations Including Results of Phase 2b Randomized, Open-Label Study of Lower Doses of Quizartinib in FLT3 ITD Positive Relapsed Refractory Acute Myeloid Leukemia (AML) Patients SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55(th) Annual ASH Conference in New...

2013-12-05 23:23:43

RnRMarketResearch.com adds “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018” to its store. Dallas, Texas (PRWEB) December 05, 2013 The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant...

2013-12-05 16:25:29

CHESTERBROOK, Pa., Dec. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the Oppenheimer 24(th) Annual Conference to be held December 10-11, 2013 at the Crown Plaza in New York. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30 a.m. ET on Wednesday, December 11, 2013. (Logo:...

2013-12-04 16:25:59

BELLEVILLE, ON, Dec. 4, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a study approved for publication in the Journal of Food Protection demonstrates that Verotoxigenic Escherichia coli (VTEC) results in a cost of $403.9 million per year in Canada related to primary infections and long-term health outcomes. More than 93% of the VTEC infections are caused by the O157...

2013-12-04 12:26:42

TARRYTOWN, N.Y., Dec. 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Oppenheimer 24(th) Annual Healthcare Conference on Wednesday, December 11, 2013. The presentation is scheduled for 10:05 a.m. Eastern Time and may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days. About Regeneron...